India vs Sierra Leone: Average cost of multi drug-resistant tuberculosis treatment
India
400 constant 2022 US$
in 2024
Sierra Leone
369 constant 2022 US$
in 2024
India rank
87th
Sierra Leone rank
88th
Average cost of multi drug-resistant tuberculosis treatment over time
- India
- Sierra Leone
How they compare
India currently reports 400 constant 2022 US$ against 369 constant 2022 US$ in Sierra Leone, a difference of 31 constant 2022 US$.
That makes India's figure about 1.1 times Sierra Leone's.
The two have swapped places 2 times across 6 shared years of data; in 2017 it was India ahead.
India ranks 87th and Sierra Leone ranks 88th of 92 countries.
Across the 2 decades both report, India averaged higher in 1 and Sierra Leone in 1.
Head to head by decade
| Decade | India | Sierra Leone | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,700 constant 2022 US$ | 1,403 constant 2022 US$ | 297 constant 2022 US$ | India |
| 2020s | 476.67 constant 2022 US$ | 1,564 constant 2022 US$ | 1,087 constant 2022 US$ | Sierra Leone |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, India or Sierra Leone?
- India, at 400 constant 2022 US$ against 369 constant 2022 US$ in Sierra Leone as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between India and Sierra Leone?
- 31 constant 2022 US$, with India ahead.
- How many years of comparable data are there for India and Sierra Leone?
- 6 years are reported by both, from 2017 to 2024.
- How do India and Sierra Leone rank globally for average cost of multi drug-resistant tuberculosis treatment?
- India ranks 87th and Sierra Leone ranks 88th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.